Fatal illusion of cheap medicine: how Supreme Court ruling exposes rot in Sri Lanka’s health procurement

By Nishel Fernando

Colombo, April 2 (Daily Mirror) - In the complex ecosystem of national healthcare, the pill a patient swallows is the final link in a long, often invisible chain of science, manufacturing logistics, and regulation. For Sri Lanka, industry experts have long warned that this chain is structurally unsound, stretched to a breaking point by a misplaced national fixation on the price of medicine over its quality, efficacy, and safety.

The prevailing consensus among veteran pharmaceutical professionals and clinicians—that the country’s regulatory framework has become outdated, reactive, and dangerously porous—has now been spectacularly vindicated by the highest court in the land. The landmark Supreme Court judgment in the consolidated cases of SC FR 65/2023 and SC FR 82/2023 is not merely a legal verdict; it is a devastating autopsy of a healthcare system where the pursuit of cheap alternatives and the abuse of emergency loopholes paved the way for unprecedented institutional corruption. Delivered on March 27, 2026, the ruling serves as the ultimate case study proving the dire warnings previously raised regarding the sector’s trajectory.

Stemming from fundamental rights petitions filed by Transparency International Sri Lanka and public interest litigators, the judgment forensically dismantles the arbitrary and capricious procurement of thirty-eight medical supplies from an unregistered Indian supplier, Savorite Pharmaceuticals (Pvt) Limited. The Court found former Minister of Health Keheliya Rambukwella, alongside the highest echelons of the Ministry of Health and the National Medicines Regulatory Authority, responsible for orchestrating a procurement process that was entirely unlawful, null, and void. By using this ruling as a mirror, the entire healthcare sector is forced to confront the catastrophic consequences of compromising quality for makeshift, price-driven procurement.

A manufactured emergency and the collapse of due process

The anatomy of this scandal illustrates precisely how the foundational pillars of pharmaceutical integrity are easily bypassed when the system allows subjective criteria like urgency to override objective standards of quality. The crisis was manufactured through a Cabinet Memorandum submitted by the former Minister of Health on October 25, 2022. In it, he sought approval to import stocks of medical supplies using the Indian Credit Line, justifying the unsolicited bid by falsely claiming that the available stocks of these essential medicines were at a zero level. This artificially engineered panic was the key used to unlock the treasury and bypass stringent procurement guidelines.

However, the Supreme Court meticulously exposed this narrative as a fabrication. The succeeding Secretary to the Ministry of Health confirmed to the Court that there was no such shortage, and that stock positions were at a satisfactory level. Furthermore, the Court highlighted that the then Minister of Finance had explicitly warned that because the supplier was selected on an unsolicited basis, the prices and quality should be reviewed by the Cabinet Appointed Negotiation Committee or the Health Sector Emergency Procurement Committee. These warnings were deliberately ignored. Instead, the officials plunged ahead with direct contracting, a method that the National Procurement Agency guidelines strictly limit to exceptional circumstances where specific criteria are met, none of which applied to Savorite Pharmaceuticals.

Weaponizing the waiver of registration

The mechanism used to circumvent the law is perhaps the most glaring structural flaw in the current regulatory framework: the Waiver of Registration. Section 109 of the National Medicines Regulatory Authority Act No. 05 of 2015 allows the authority to grant permission to import unregistered medicines in special circumstances, such as a national emergency or to save a life. In this case, the Waiver of Registration was weaponized. The Ministry of Health’s Medical Supplies Division requested the waiver simply because the Cabinet had approved the direct purchase, and the regulator compliantly issued it without conducting the rigorous due diligence required. This transformation of an exceptional emergency clause into a standard operating procedure for unsolicited, unregistered bids represents a complete abdication of the regulator's statutory duty to protect the public.

The catastrophic failure in quality assurance that followed is a stark reminder of why registration and testing cannot be compromised. When the Supreme Court issued an interim order suspending the use of the imported consignments until their safety, efficacy, and quality could be verified, the ensuing investigations revealed a terrifying reality. A five-member expert committee appointed by the National Medicines Regulatory Authority reviewed the test reports submitted by Savorite Pharmaceuticals and found them woefully inadequate. Out of the laboratories where the tests were performed, only one was WHO-prequalified. Complete test reports were available for only twenty-three out of the thirty-two products evaluated. When directed to submit further reports from WHO-prequalified laboratories, the supplier simply failed to do so, leaving the regulator unable to guarantee the safety of the drugs.

The economic fallacy of lowest-bidder healthcare

This total breakdown in quality control is not an isolated incident; it is the predictable culmination of the flawed regulatory shift that occurred with the enactment of the National Medicines Regulatory Authority Act in 2015. Prior to this legislation, Sri Lanka’s regulatory bedrock focused resolutely on safety, efficacy, and quality. However, driven by political imperatives and populist rhetoric, the 2015 Act introduced price and need as core criteria for drug approval.

While making medicine affordable is a noble goal, embedding price controls into the primary regulatory approval process fundamentally altered the market dynamics. It empowered the regulator to dictate market conditions, shifting the national focus away from clinical efficacy towards a relentless, race-to-the-bottom search for the cheapest available options. When price becomes the dominant metric, it creates an environment ripe for exploitation by unregistered, substandard suppliers who can easily undercut legitimate innovators because they do not invest in rigorous, WHO-standard quality assurance. The Savorite Pharmaceuticals case is the ultimate manifestation of this systemic vulnerability. The officials involved exploited the populist desire for cheap, immediate solutions, using the guise of an economic crisis to bypass the established, high-quality pharmaceutical supply chain in favour of an opaque, unsolicited alternative. The resulting influx of unverified, potentially dangerous drugs masks severe risks to public health behind a thin, easily shattered veneer of economic efficiency.

The true cost of compromised standards

The financial and human cost of this compromise is staggering, entirely debunking the myth that bypassing quality controls saves the state money. The Supreme Court decisively ordered that no payments be made to Savorite Pharmaceuticals for the thirty-eight medical supplies. More significantly, in a historic move to enforce accountability and protect the public trust, the Court imposed unprecedented personal financial liabilities on the perpetrators. The former Minister of Health was ordered to pay Rs. 75 million to the state, while the former Secretary to the Ministry of Health, the former Chairman of the National Medicines Regulatory Authority, its former Chief Executive Officer, and the former Director of the Medical Supplies Division were each ordered to pay Rs. 50 million. Yet, these multi-million-rupee fines are merely a token reflection of the true cost to the nation. When the state bypasses quality testing, it inevitably absorbs the downstream costs of adverse patient reactions, treatment failures, and the squandering of public funds on legal battles and remedial procurements. The Court’s directive for the Commission to Investigate Allegations of Bribery or Corruption to initiate action further highlights the deep economic and reputational damage inflicted upon the state machinery.

A mandate for structural reform and industry dialogue

Navigating out of this pharmaceutical crossroads requires an immediate and comprehensive structural overhaul. The call for reform is no longer just an industry plea; it is now a judicial mandate. The National Medicines Regulatory Authority must be insulated from political interference and returned to its foundational mandate: serving as an independent, scientifically driven gatekeeper of safety, efficacy, and quality. The loopholes that permit the arbitrary declaration of emergencies and the subsequent issuance of registration waivers must be permanently closed.

The procurement of medicines must be subjected to stringent, transparent reviews that prioritize clinical outcomes over the lowest initial bid. Crucially, this structural reform cannot happen in a vacuum. It necessitates a transparent and sustained dialogue between the government, the regulator, and the legitimate, established pharmaceutical industry. For years, veteran industry professionals have warned about the vulnerabilities that this Supreme Court ruling has now laid bare. Their expertise must be integrated into the policy-making process to construct a supply chain that is resilient and capable of guaranteeing modern, effective treatments for all Sri Lankans. The industry's capacity for innovation cannot be leveraged if legitimate manufacturers are constantly forced to compete on an unlevel playing field against unregistered suppliers shielded by arbitrary state waivers and opaque procurement practices.

Prioritizing uncompromised quality

Ultimately, the Supreme Court ruling is a definitive line drawn in the sand. It serves as a stark, indisputable reminder that in the realm of national healthcare, compromising quality for the sake of price is not a strategic administrative decision; it is a dangerous and illegal gamble with human lives. The true value of a medical product is found not in a discounted price tag or an unsolicited bid, but in its proven safety, clinical efficacy, and the rigorous, uncompromising quality assurance protocols that back it. As Sri Lanka looks to rebuild its shattered healthcare procurement system, the lessons from this judicial intervention must be the cornerstone of future policy. The national mindset must irrevocably shift, acknowledging that true fiscal and moral responsibility lies in funding a transparent, accountable system that delivers uncompromised quality to every citizen.